| Abstrakt: |
A retrospective US study published in Drug Safety found no association between the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors and the risk of invasive breast cancer in women with type 2 diabetes mellitus. The study analyzed data from over 150,000 women and identified 2,154 cases of invasive breast cancer over a 2.2-year follow-up period. The researchers concluded that there was no significant association between SGLT2 inhibitor use and breast cancer risk, but they noted the need for further studies with longer follow-up periods to confirm these findings. [Extracted from the article] |
Full text from SpringerLink